US Clinical Trial

Are you living with moderate-to-severe hidradenitis suppurativa (HS)?

If so, consider joining the Regulate-HS trial, a clinical trial for adults with moderate-to-severe hidradenitis suppurativa, also known as acne inversa, investigating a new potential treatment.

Trial Overview

Are you living with moderate-to-severe hidradenitis suppurativa (HS)?

If so, consider joining the SBT777101-02 trial, a clinical trial for adults with moderate-to-severe hidradenitis suppurativa, also known as acne inversa, investigating a new potential treatment.

Trial Clinic Locations

What is the Regulate-HS trial?

The Regulate-HS clinical trial is for adults living with hidradenitis suppurativa (HS), also known as acne inversa. The trial will test a new investigational cell therapy product, SBT777101, to determine if it can safely and effectively treat symptoms of HS in patients who have a history of inadequate response to previous therapies designed to treat HS.

SBT777101 is not approved by the FDA for the treatment of HS as the safety and efficacy have not yet been established.

Who can join the Regulate-HS trial?

You may be eligible to join the trial if you meet the following requirements:

18 to 70 years of age

Confirmed diagnosis of hidradenitis suppurativa (HS), also known as acne inversa

Must have a history of inadequate response to previous medications or therapies designed to treat HS

Must be willing to undergo skin biopsies

Cannot have a history of inflammatory or autoimmune disease, including but not limited to Crohn’s disease

Must be willing to comply with all trial requirements

*Additional trial requirements will apply and be discussed with you by your trial team.

What will happen during the trial?

Trial participants can expect the following:

Review & Sign the Informed Consent Form
The Informed Consent Form (ICF) contains information about the trial including its goals, duration, benefits, risks, tests and procedures.
Screening Period (About 4 Weeks)
Receive trial health assessments such as physical assessments, medical history, and demographic information to confirm if you qualify for the trial. This period will have an optional skin biopsy.
Pre-Treatment Period & SBT777101 Preparation (about 6 weeks, up to 6 months)
Participants will undergo pre-treatment health assessments such as apheresis to manufacture STB777101 and to determine if it is safe for the participant to receive SBT777101. This will also include a skin biopsy.
Trial Treatment Period & Trial Health Assessments (about 11 Months)
Participants who qualify will receive a one-time single dose of SBT777101 administered intravenously and will be monitored overnight. After infusion, participants will receive ongoing trial health assessments for about 11 months and will have additional skin biopsy.
Follow-up Period (up to 15 years)
Continue to the long-term follow up period for up to 15 years. Trial clinic staff will provide more information.

Participation in a clinical trial is voluntary. You can ask any questions you have and may leave the trial at any time, for any reason.

Interested in the Regulate-HS trial?

Visit the trial clinic map or clinicaltrials.gov to find a clinic near you.

Trial Clinic Locations

About the Trial Therapy

What is the trial cell therapy?

SBT777101 is a cell therapy, meaning it is made from the patient’s own immune cells called regulatory T cells. Blood cells are collected from the patient with hidradenitis suppurativa (HS) and then modified to have a special protein on their surface that targets a specific marker related to inflammatory diseases such as HS. After expanding and stimulating these modified cells, they are given back to the patient. Strict procedures are in place to ensure the product's identity and safety at every step, from cell collection to administration.

Will I receive the trial therapy?

If you qualify to participate in the Regulate-HS trial, you will be placed in a dose-level cohort and will undergo a one-time intravenous (IV) administration of SBT777101 on Day 1 of the trial.

What is an “investigational therapy”?

Investigational means the trial medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Investigational therapies such as SBT777101 can only be used in clinical trials like the Regulate-HS trial.

Hidradenitis Suppurativa

What is hidradenitis suppurativa (HS)?

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic skin condition characterized by painful bumps and abscesses forming beneath the skin. It commonly occurs on areas of the body that experience friction, such as underarms, breasts, inner thighs, and the groin. In addition to causing pain, HS can result in permanent scarring and, if untreated, may lead to infections in severe cases. Women are three times more likely than men to develop HS, and individuals who are obese or smoke face a higher risk.

Symptoms of HS include:

  • Painful pea-sized lumps under the skin
  • Recurring abscesses that drain fluid
  • Blackheads
  • Itchiness
  • Pain

Where can I learn more?

You can learn more about HS using the following resources:

About Clinical Trials

Here are some common questions and answers about trial participation.

If you have additional questions about participating in a clinical research trial, contact a trial clinic near you.

Trial Clinic Locations

Find a trial clinic near you!

Use the filters, map, and listing to find the trial clinic closest to you. Contact the trial clinic to learn more.

Copyright © 2024 Medpace